Healthcare Industry News: NSCLC
News Release - April 26, 2016
Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology TherapiesTINLEY PARK, Ill., April 25, 2016 -- (Healthcare Sales & Marketing Network) -- Hematogenix, an industry leader in the field of integrated pathology services for drug development and clinical testing, announces the availability of the FDA approved PD-L1 companion diagnostic assays PD-L1 IHC 22C3 pharmDx for KEYTRUDAŽ, Merck's Anti-PD-1 therapy for metastatic non-small cell lung cancer, and PD-L1 IHC 28-8 pharmDx, a complementary diagnostic assay to support Bristol-Myers Squibb's OPDIVOŽ anti-PD-1 therapy for non-squamous non-small cell lung cancer. Both kits are available through Dako, an Agilent Technologies company. Learn more about Hematogenix's comprehensive biomarker development and testing services at www.hematogenix.com.
Dako developed PD-L1 IHC 22C3 pharmDx in partnership with Merck & Co., Inc., maker of the anti-PD-1 therapy KEYTRUDAŽ (pembrolizumab). KEYTRUDA is approved by the FDA to treat patients with metastatic NSCLC whose tumors express PD-L1 as determined by the companion diagnostic assay and who have disease progression on or after platinum-containing chemotherapy.
PD-L1 IHC 28-8 pharmDx, also by Dako, was approved as a complementary diagnostic to detect PD-L1 protein expression levels and to help physicians determine which patients may benefit most from treatment with Bristol-Myers Squibb's OPDIVOŽ (nivolumab). OPDIVOŽ has extended indication, from melanoma and non-small cell lung cancer to renal cell cancer.
"The immuno-oncology agents Keytruda and Opdivo have already transformed the cancer care landscape," said Hytham Al-Masri, M.D., CEO and Medical Director of Hematogenix. "The addition of these two tests to our already existing menu of PD-L1 assays helps to identify patients who may benefit from immunotherapy. With the availability of new companion diagnostics, we continue to see how immune therapies can benefit patients across a wide range of tumors."
Hematogenix, is a CAP/CLIA certified laboratory with a full complement of board-certified clinical, anatomic and research pathologists to provide consultation and guidance for all aspects of their pharma and diagnostic services. The company offers a comprehensive array of biomarker development and testing services designed to navigate the complexities of human subject clinical trials. Hematogenix provides logistic management of tissue and sample procurement, distributes collection kits and contributes to standards and procedures required for initiating a clinical trial. Powered by a state-of-the-art laboratory information system, Hematogenix complies with rigorous chain-of-custody and specimen-management practices.
Source: Hematogenix Laboratory Services
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.